Dímero D y pronóstico de letalidad en pacientes diabéticos con COVID-19
Palabras clave:
Coagulopatía; diabetes mellitus; mortalidad; pronóstico; SARS-CoV-2
Resumen
La crisis sanitaria generada por la enfermedad por coronavirus 2019 o COVID-19 debido a su rápida expansión y al poco conocimiento de este nuevo padecimiento, ocasionó la muerte de gran cantidad de personas en el mundo, razón por la que, los profesionales de salud se vieron en la tarea de identificar posibles factores de riesgo que permitan dar un pronóstico de la gravedad. El objetivo de este estudio fue analizar las concentraciones de dímero D y el pronóstico de letalidad en pacientes diabéticos con COVID-19. El estudio consistió en una investigación de diseño documental con carácter descriptivo y exploratorio el cual permitió seleccionar bajo criterios de inclusión artículos publicados en los últimos años (2019-2022) relacionados al tema. Se evidencia una asociación en la alteración (hasta diez veces más su valor referencial) de las concentraciones séricas de dímero D y la mortalidad reportada, la cual se ubicó en 55,67% de los pacientes con diabetes mellitus y COVID-19. Los casos graves representaron el 19,7% en estos pacientes. El dímero D, además del TP y plaquetas tienen un valor pronóstico en los pacientes diabéticos con COVID-19, por lo que se valida su uso como biomarcador de severidad y letalidad en este grupo.
Descargas
La descarga de datos todavía no está disponible.
Citas
1. Ahmed AS, A. W.-N. (2021). Chigurupati S, Elgharabawy RM. Factors Affecting the Incidence, Progression, and Severity of COVID-19 in Type 1 Diabetes Mellitus. . Biomed Res Int.
2. Alsayer RM, A. H. (2021). Clinical and epidemiological characteristics of COVID-19 mortality in Saudi Arabia. . Saudi Med J. , 1083-1094.
3. Badedi M, D. H. (2021). Epidemiological and Clinical Characteristics of Deceased COVID-19 Patients. Int J Gen Med.
4. Caballero AE, C. A. (2020). COVID-19 in people living with diabetes: An international consensus. J Diabetes Complications., 34. https://dx.doi.org/10.1016%2Fj.jdiacomp.2020.107671
5. Cheng X, X. S. (2021). Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study. . Life Sci.
6. Ciardullo S, Z. F. (2021). Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. . J Endocrinol Invest.
7. Corona G, P. A. (2021). Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev Endocr Metab Disord. .
8. Czupryniak, L. (2020). Diabetes mellitus e infección por SARS-CoV-2: riesgo, curso e indicaciones de actuación. Rev Médica Empendium., 41–5. https://empendium.com/manualmibe/COVID19/238194,diabetes-mellitus-e-infeccion-por-sars-cov-2-riesgo-curso-e-indicaciones-de-actuacion
9. Debi H, I. Z. (2022). Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. . Expert Rev Endocrinol Metab., 83-93. https://doi.org/10.1080/17446651.2022.2002146.
10. Deng, S. Q., & Peng, H. (2020). Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. . J Clin Med. . https://doi.org/10.3390/jcm9020575
11. Dessie ZG, Z. T. (2021). Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. . BMC Infect Dis. https://doi.org/10.1186/s12879-021-06536-3
12. Gogate N, L. D. (2021). COVID-19 biomarkers and their overlap with comorbidities in a disease biomarker data model. . Brief Bioinform.
13. Grajales JL, A.-H. N.-H.-L. (2020). COVID-19 y diabetes. Retos, Implicaciones y manejo durante la pandemia. . CES Med.
14. Huang C, W. Y. (2020). features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. https://dx.doi.org/10.1016%2FS0140-6736(20)30183-5
15. Itu ZT, A. M. (2022). Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. . Expert Rev Endocrinol Metab, 83-93.
16. J A Barrionuevo Mejía, G. L. (2021). Complicaciones en pacientes diabeticos con COVID-19. Enfermería Investig, 46. http://dx.doi.org/10.31243/ei.uta.v6i5.963.2021
17. Liao D, Z. F. (2020). Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. . Lancet Haematol.
18. Martos Pérez F, L. d. (2021). Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. Rev Clin Esp.
19. Mata-Cases M, F.-N. J. (2019). Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study. BMJ Open.
20. Moreno, G., Carbonell, R., Bodi, A., & Rodriguez, A. (2021). Revisión sistemática sobre la utilidad pronóstica del dímero-D, coagulación intravascular diseminada y tratamiento anticoagulante en pacientes graves con COVID-19. Medicina Intensiva, 45(1), 42-55.
21. Muhammad R, O. R. (2022). Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. J Racial Ethn Health Disparities.
22. Nassar M, D. A. (2021). Diabetes Mellitus and COVID-19: Review Article. . Diabetes Metab Syndr. https://doi.org/10.1016/j.dsx.2021.102268
23. Niquini RP, L. R. (2020). Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population. . Cad Saude Publica.
24. Organización Mundial de la Salud. (2021). Nuevo coronavirus 2019. https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019%0
25. Oudkerk M, B. H. (2020). Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the national institute for public health of the Netherlands. . Radiology. .
26. Ramírez-Plascencia LE, V.-L. A.-M.-V.-I.-F. (2022). Factors Possibly Associated with Mortality in Intubated COVID-19 Patients: A Retrospective Study. . Pathogens. .
27. Richardson S, H. J. (2020). Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. . JAMA .
28. Sáenz, Sierra, & Garcia. (2020). Predictores se Mortalidad en Pacientes con COVID-19. Archivos de Médicina, 16(26).
29. Shang J, W. Q. (2021). The Relationship Between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China. . Am J Med. . https://doi.org/10.1016/j.amjmed.2020.05.033.
30. Shrestha E, C. M. (2021). Type 2 diabetes is associated with increased risk of critical respiratory illness in patients COVID-19 in a community hospital. . Obes Med. https://doi.org/10.1016/j.obmed.2020.100316.
31. Sutter W, D. B. (2021). Critical COVID-19 France Investigators Et al. Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. . Diabetes Metab.
32. Tomar BS, S. M. (2021). NIMS COVID 19 Investigator Group. Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study. Int J Gen Med.
33. Torres Criollo LM, R. C. (2020). Variables clínicas y paraclínicas predictoras de pronóstico en pacientes con COVID- 19: Revisión Sistemática. Arch Venez Farmacol y Ter., 667–74. https://doi.org/10.5281/zenodo.4256990
34. Torres, M., Caracas-Portillo, N. A., Peña-Aparicio, B., Juárez-Rojas, J. G., Medina, A. X., & Martínez, M. d. (2020). Infección por coronavirus en pacientes con diabetes. Cardiovascular and Metabolic Science.
35. Varikasuvu SR, V. S. (2021). Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19. J Thromb Thrombolysis.
36. Wang D, H. B. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 10.1001/jama.2020.1585. , 1061-1069.
37. World Health Organization. (2020). WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected
38. Wu, W., & McGoogan, J. M. (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19). Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention [Internet]., 1239–42. https://doi.org/10.1001/jama.2020.2648
39. Zhang JJ, D. X. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 75(7), 1730-1741. https://doi.org/10.1111/all.14238. PMID: 32077115.
2. Alsayer RM, A. H. (2021). Clinical and epidemiological characteristics of COVID-19 mortality in Saudi Arabia. . Saudi Med J. , 1083-1094.
3. Badedi M, D. H. (2021). Epidemiological and Clinical Characteristics of Deceased COVID-19 Patients. Int J Gen Med.
4. Caballero AE, C. A. (2020). COVID-19 in people living with diabetes: An international consensus. J Diabetes Complications., 34. https://dx.doi.org/10.1016%2Fj.jdiacomp.2020.107671
5. Cheng X, X. S. (2021). Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study. . Life Sci.
6. Ciardullo S, Z. F. (2021). Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. . J Endocrinol Invest.
7. Corona G, P. A. (2021). Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Rev Endocr Metab Disord. .
8. Czupryniak, L. (2020). Diabetes mellitus e infección por SARS-CoV-2: riesgo, curso e indicaciones de actuación. Rev Médica Empendium., 41–5. https://empendium.com/manualmibe/COVID19/238194,diabetes-mellitus-e-infeccion-por-sars-cov-2-riesgo-curso-e-indicaciones-de-actuacion
9. Debi H, I. Z. (2022). Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. . Expert Rev Endocrinol Metab., 83-93. https://doi.org/10.1080/17446651.2022.2002146.
10. Deng, S. Q., & Peng, H. (2020). Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. . J Clin Med. . https://doi.org/10.3390/jcm9020575
11. Dessie ZG, Z. T. (2021). Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. . BMC Infect Dis. https://doi.org/10.1186/s12879-021-06536-3
12. Gogate N, L. D. (2021). COVID-19 biomarkers and their overlap with comorbidities in a disease biomarker data model. . Brief Bioinform.
13. Grajales JL, A.-H. N.-H.-L. (2020). COVID-19 y diabetes. Retos, Implicaciones y manejo durante la pandemia. . CES Med.
14. Huang C, W. Y. (2020). features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. https://dx.doi.org/10.1016%2FS0140-6736(20)30183-5
15. Itu ZT, A. M. (2022). Association of serum C-reactive protein (CRP) and D-dimer concentration on the severity of COVID-19 cases with or without diabetes: a systematic review and meta-analysis. . Expert Rev Endocrinol Metab, 83-93.
16. J A Barrionuevo Mejía, G. L. (2021). Complicaciones en pacientes diabeticos con COVID-19. Enfermería Investig, 46. http://dx.doi.org/10.31243/ei.uta.v6i5.963.2021
17. Liao D, Z. F. (2020). Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. . Lancet Haematol.
18. Martos Pérez F, L. d. (2021). Comorbidity and prognostic factors on admission in a COVID-19 cohort of a general hospital. Rev Clin Esp.
19. Mata-Cases M, F.-N. J. (2019). Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study. BMJ Open.
20. Moreno, G., Carbonell, R., Bodi, A., & Rodriguez, A. (2021). Revisión sistemática sobre la utilidad pronóstica del dímero-D, coagulación intravascular diseminada y tratamiento anticoagulante en pacientes graves con COVID-19. Medicina Intensiva, 45(1), 42-55.
21. Muhammad R, O. R. (2022). Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection. J Racial Ethn Health Disparities.
22. Nassar M, D. A. (2021). Diabetes Mellitus and COVID-19: Review Article. . Diabetes Metab Syndr. https://doi.org/10.1016/j.dsx.2021.102268
23. Niquini RP, L. R. (2020). Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population. . Cad Saude Publica.
24. Organización Mundial de la Salud. (2021). Nuevo coronavirus 2019. https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019%0
25. Oudkerk M, B. H. (2020). Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the national institute for public health of the Netherlands. . Radiology. .
26. Ramírez-Plascencia LE, V.-L. A.-M.-V.-I.-F. (2022). Factors Possibly Associated with Mortality in Intubated COVID-19 Patients: A Retrospective Study. . Pathogens. .
27. Richardson S, H. J. (2020). Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. . JAMA .
28. Sáenz, Sierra, & Garcia. (2020). Predictores se Mortalidad en Pacientes con COVID-19. Archivos de Médicina, 16(26).
29. Shang J, W. Q. (2021). The Relationship Between Diabetes Mellitus and COVID-19 Prognosis: A Retrospective Cohort Study in Wuhan, China. . Am J Med. . https://doi.org/10.1016/j.amjmed.2020.05.033.
30. Shrestha E, C. M. (2021). Type 2 diabetes is associated with increased risk of critical respiratory illness in patients COVID-19 in a community hospital. . Obes Med. https://doi.org/10.1016/j.obmed.2020.100316.
31. Sutter W, D. B. (2021). Critical COVID-19 France Investigators Et al. Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. . Diabetes Metab.
32. Tomar BS, S. M. (2021). NIMS COVID 19 Investigator Group. Prevalence of Symptoms in Patients Discharged from COVID Care Facility of NIMS Hospital: Is RT PCR Negativity Truly Reflecting Recovery? A Single-Centre Observational Study. Int J Gen Med.
33. Torres Criollo LM, R. C. (2020). Variables clínicas y paraclínicas predictoras de pronóstico en pacientes con COVID- 19: Revisión Sistemática. Arch Venez Farmacol y Ter., 667–74. https://doi.org/10.5281/zenodo.4256990
34. Torres, M., Caracas-Portillo, N. A., Peña-Aparicio, B., Juárez-Rojas, J. G., Medina, A. X., & Martínez, M. d. (2020). Infección por coronavirus en pacientes con diabetes. Cardiovascular and Metabolic Science.
35. Varikasuvu SR, V. S. (2021). Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19. J Thromb Thrombolysis.
36. Wang D, H. B. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 10.1001/jama.2020.1585. , 1061-1069.
37. World Health Organization. (2020). WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected
38. Wu, W., & McGoogan, J. M. (2020). Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19). Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention [Internet]., 1239–42. https://doi.org/10.1001/jama.2020.2648
39. Zhang JJ, D. X. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 75(7), 1730-1741. https://doi.org/10.1111/all.14238. PMID: 32077115.
Publicado
2022-11-26
Cómo citar
Silvana Nancy Orozco Alvarez, & Narcisa Liliana Duran Avila. (2022). Dímero D y pronóstico de letalidad en pacientes diabéticos con COVID-19. Revista Científica FIPCAEC (Fomento De La investigación Y publicación científico-técnica multidisciplinaria). ISSN : 2588-090X . Polo De Capacitación, Investigación Y Publicación (POCAIP), 7(4), 1952-1972. Recuperado a partir de https://fipcaec.com/index.php/fipcaec/article/view/715
Sección
Artículos de Investigación
